Special Drug Use Investigation for LAMICTAL Bipolar

NCT01428518 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1036

Last updated 2016-04-25

No results posted yet for this study

Summary

This post-marketing surveillance study is designed to collect and assess information on safety and effectiveness of lamotrigine tablets in patients with bipolar disorder in routine clinical practice.

("LAMICTAL" is a trademark of the GlaxoSmithKline group of companies.)

Conditions

Interventions

DRUG

Lamotrigine tablets

Administered according to the prescribing information in the locally approved label by the authorities.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-01-31
Completion
2016-01-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01428518 on ClinicalTrials.gov